Agios Pharmaceuticals (AGIO) Current Leases (2019 - 2026)

Agios Pharmaceuticals has reported Current Leases for 8 years, with the latest figure at $18.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 9.36% year-over-year to $18.8 million; the trailing twelve-month figure through Mar 2026 stood at $18.8 million (up 9.36% YoY), and the FY2025 full-year result was $18.4 million, up 9.6% from the prior year.
• Current Leases for Q1 2026 stood at $18.8 million, up from $18.4 million in the prior quarter.
• The five-year high for Current Leases was $18.8 million in Q1 2026, with the low at $167000.0 in Q2 2022.
• Historically, Current Leases has averaged $14.8 million across 5 years, with a median of $15.4 million in 2024.
• Annual changes were most pronounced in 2022 — Current Leases plunged 80.1% — and 2023, when it soared 8478.44%.
• Agios Pharmaceuticals' Current Leases stood at $13.7 million in 2022, then grew by 9.84% to $15.0 million in 2023, then gained by 11.81% to $16.8 million in 2024, then rose by 9.6% to $18.4 million in 2025, then grew by 2.25% to $18.8 million in 2026.
• The last three Current Leases figures came in at $18.8 million (Q1 2026), $18.4 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.